Abstract
Multiple sclerosis is a chronic, unpredictable, and disabling disease. Significant advances have been made in recent years supporting an earlier, more accurate, diagnosis and have led to more than 15 disease-modifying therapies approved by the Food and Drug Administration for relapsing forms of multiple sclerosis. Disease-modifying therapies are now being classified into categories based on level of efficacy. Strategies to use disease-modifying therapies earlier and in a more customizable manner are also emerging. A clinical case study will be used throughout this pearl to review the disease-modifying therapies and use patient-specific factors to develop and provide recommendations on therapeutic strategies for individuals with relapsing forms of multiple sclerosis.
Author supplied keywords
Cite
CITATION STYLE
Klocke, S., & Hahn, N. (2019). Multiple sclerosis. Mental Health Clinician, 9(6), 349–358. https://doi.org/10.9740/mhc.2019.11.349
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.